You are here: Home / Sites / Eastern Virginia Medical School / Semmes, John

Semmes, John (Ph.D.)

PI, Eastern Virginia Medical School, (757) 446-5904

Contact Information

Fax: 757 446-5766
EDRN Principal Investigator
Microbiology and Molecular Ce

To update contact information, please visit the Data Management and Coordinating Center.

Open Protocols

Protocol Name Biomarkers Datasets
Body Fluids as a Source of Diagnostic Biomarkers 0 0
Body Fluids as a Source of Diagnostic Biomarkers: Breast 0 0
Collaborative study on SELDI biomarker discovery and serum protein profiling of lung cancers 0 0
Detecting breast cancer protein signatures in body fluid 0 0
Establishment of a serum standard for use in high-throughput proteomic 0 0
SELDI and LC-MS/MS discovery and profiling study of hepatocarcinomas 0 0
SELDI Profiling of serum and urine from patients with urologic disease in support of bladder cancer studies 0 0
Detection of Serum Markers of Breast Cancer by SELDI 0 0
EDRN Pre-Validation of Metabolic Biomarkers of Prostate Cancer: Follow up EDRN Challenge 0 0
EDRN Pre-Validation of Multiplex Biomarker in Urine 2 0
HNPCC colon cancer-associated SELDI mass spectrometry protein profiles in serum 0 0
Upgrading Reference Set 0 0

Closed Protocols

Protocol Name Biomarkers Datasets
Body Fluids as a Source of Diagnostic Biomarkers: Prostate 0 0
Early Detection of Cancer by Affinity Mass Spectrometry-Set Aside funds 0 0
Protein profiling for detection of high risk breast cancer 0 0
Proteomic Profiling of Serum and Other Body Fluids for the Early Detection of Colon Cancers 0 0
SELDI Phase I: Assay Validation-Prostate 0 1
SELDI Validation Study Phase II 0 3
EDRN-WHI Pre-Clinical Colon Ca Specimens 0 9


Publication Name PubMed ID Journal
Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. 12171882 Clin. Cancer Res.
Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. 12097261 Cancer Res.
Data reduction using a discrete wavelet transform in discriminant analysis of very high dimensionality data. 12762451 Biometrics
A novel approach toward development of a rapid blood test for breast cancer. 14499014 Clin. Breast Cancer
The "omics" haystack: defining sources of sample bias in expression profiling. 16120944 Clin. Chem.
Measurement reproducibility in the early stages of biomarker development. 15665389 Dis. Markers
Resampling and deconvolution of linear time-of-flight records for enhanced protein profiling. 16637003 Rapid Commun. Mass Spectrom.
Generation of a baculovirus recombinant prostate-specific membrane antigen and its use in the development of a novel protein biochip quantitative immunoassay. 10833385 Protein Expr. Purif.
Feature extraction in the analysis of proteomic mass spectra. 16502467 Proteomics
Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. 11290567 Am. J. Pathol.
Serum protein profiles to identify head and neck cancer. 15014013 Clin. Cancer Res.
A novel approach for clustering proteomics data using Bayesian fast Fourier transform. 15769836 Bioinformatics
Functional clustering algorithm for high-dimensional proteomics data. 16046812 J. Biomed. Biotechnol.
Proteomic approaches to biomarker discovery in prostate and bladder cancers. 11721637 Proteomics
Deconvolution filters to enhance resolution of dense time-of-flight survey spectra in the time-lag optimization range. 16636999 Rapid Commun. Mass Spectrom.
Mining the low molecular weight proteome of blood. 21136732 Proteomics Clin Appl
Application of mass spectrometry to the discovery of biomarkers for detection of prostate cancer. 16552720 J. Cell. Biochem.
Overexpression of alpha-defensin is associated with bladder cancer invasiveness. 16520271 Urol. Oncol.
Serum biomarkers to differentiate benign and malignant mammographic lesions. 17481542 J. Am. Coll. Surg.
Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers. 16760258 Mol. Cell Proteomics
Clinical proteomics: A need to define the field and to begin to set adequate standards. 21136664 Proteomics Clin Appl
Proteomic strategies for biomarker identification: progress and challenges. 11249741 Curr. Opin. Mol. Ther.
Serum, salivary and tissue proteomics for discovery of biomarkers for head and neck cancers. 15723595 Expert Rev. Mol. Diagn.
Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. 15709174 Clin. Cancer Res.
Enhancement of sensitivity and resolution of surface-enhanced laser desorption/ionization time-of-flight mass spectrometric records for serum peptides using time-series analysis techniques. 15550476 Clin. Chem.
Proteinchip(R) surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. 12497173 Prostate Cancer Prostatic Dis.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. 18606634 Clin. Chem.
Identification of patients with head and neck cancer using serum protein profiles. 14732777 Arch. Otolaryngol. Head Neck Surg.
Selective capture of prostatic basal cells and secretory epithelial cells for proteomic and genomic analysis. 15283892 Urol. Oncol.
Optimization of MALDI-TOF MS detection for enhanced sensitivity of affinity-captured proteins spanning a 100 kDa mass range. 17918874 J. Proteome Res.
Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samples. 18043497 Laryngoscope
Defining the role of mass spectrometry in cancer diagnostics. 15466969 Cancer Epidemiol. Biomarkers Prev.
Expression of genes and proteins specific for prostate cancer. 15535438 J. Urol.
Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. 15112261 Cancer
SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. 15258337 Dis. Markers
Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. 15383419 Ann. Surg. Oncol.
Protein profiling in urine for the diagnosis of bladder cancer. 15277356 Clin. Chem.

To update protocols, publications, biomarkers, or science data, please contact the Informatics Center.


700 W. Olney Road, P.O. Box 1980
Eastern Virginia Medical School

To update addresses, please visit the Data Management and Coordinating Center.

🔜 Data-Sci Workshop
The EDRN Biomarker Data Science Workshop is coming this August, 2020. More details available soon.
Announcement 03/17/2020

The EDRN Registration page will be available soon to register for the 35th EDRN Steering Committee Meeting, now scheduled to take place from June 30-July 2, 2020, in Tempe, AZ.

This icon signifies that something is happening and we kindly ask you to please wait